β-Catenin is a protein that plays a role in intercellular adhesion as well as in the regulation of gene expression. The latter role of β-catenin is associated with its oncogenic properties due to the loss of expression or inactivation of the tumor suppressor adenomatous polyposis coli (APC) or mutations in β-catenin itself. We now demonstrate that another tumor suppressor, PTEN, is also involved in the regulation of nuclear β-catenin accumulation and T cell factor (TCF) transcriptional activation in an APC-independent manner. We show that nuclear β-catenin expression is constitutively elevated in PTEN null cells and this elevated expression is reduced upon reexpression of PTEN. TCF promoter/luciferase reporter assays and gel mobility shift analysis demonstrate that PTEN also suppresses TCF transcriptional activity. Furthermore, the constitutively elevated expression of cyclin D1, a β-catenin/TCF–regulated gene, is also suppressed upon reexpression of PTEN. Mechanistically, PTEN increases the phosphorylation of β-catenin and enhances its rate of degradation. We define a pathway that involves mainly integrin-linked kinase and glycogen synthase kinase 3 in the PTEN-dependent regulation of β-catenin stability, nuclear β-catenin expression, and transcriptional activity. Our data indicate that β-catenin/TCF–mediated gene transcription is regulated by PTEN, and this may represent a key mechanism by which PTEN suppresses tumor progression.
Skip Nav Destination
Article navigation
11 June 2001
Article|
June 04 2001
Tumor Suppressor Pten Inhibits Nuclear Accumulation of β-Catenin and T Cell/Lymphoid Enhancer Factor 1–Mediated Transcriptional Activation
Sujata Persad,
Sujata Persad
aBritish Columbia Cancer Agency, Jack Bell Research Center, Vancouver V6H 3Z6, British Columbia, Canada
Search for other works by this author on:
Armelle A.Troussard,
Armelle A.Troussard
aBritish Columbia Cancer Agency, Jack Bell Research Center, Vancouver V6H 3Z6, British Columbia, Canada
Search for other works by this author on:
Timothy R. McPhee,
Timothy R. McPhee
aBritish Columbia Cancer Agency, Jack Bell Research Center, Vancouver V6H 3Z6, British Columbia, Canada
Search for other works by this author on:
David J. Mulholland,
David J. Mulholland
bThe Prostate Centre at Vancouver General Hospital, Jack Bell Research Center, Vancouver V6H 3Z6, British Columbia, Canada
Search for other works by this author on:
Shoukat Dedhar
Shoukat Dedhar
aBritish Columbia Cancer Agency, Jack Bell Research Center, Vancouver V6H 3Z6, British Columbia, Canada
bThe Prostate Centre at Vancouver General Hospital, Jack Bell Research Center, Vancouver V6H 3Z6, British Columbia, Canada
cDepartment of Biochemistry and Molecular Biology, University of British Columbia, Vancouver V6T 1Z3, British Columbia, Canada
Search for other works by this author on:
Sujata Persad
aBritish Columbia Cancer Agency, Jack Bell Research Center, Vancouver V6H 3Z6, British Columbia, Canada
Armelle A.Troussard
aBritish Columbia Cancer Agency, Jack Bell Research Center, Vancouver V6H 3Z6, British Columbia, Canada
Timothy R. McPhee
aBritish Columbia Cancer Agency, Jack Bell Research Center, Vancouver V6H 3Z6, British Columbia, Canada
David J. Mulholland
bThe Prostate Centre at Vancouver General Hospital, Jack Bell Research Center, Vancouver V6H 3Z6, British Columbia, Canada
Shoukat Dedhar
aBritish Columbia Cancer Agency, Jack Bell Research Center, Vancouver V6H 3Z6, British Columbia, Canada
bThe Prostate Centre at Vancouver General Hospital, Jack Bell Research Center, Vancouver V6H 3Z6, British Columbia, Canada
cDepartment of Biochemistry and Molecular Biology, University of British Columbia, Vancouver V6T 1Z3, British Columbia, Canada
Abbreviations used in this paper: APC, adenomatous polyposis coli; CDK, cyclin-dependent kinase; GFP, green fluorescent protein; GSK-3, glycogen synthase kinase 3; HA, hemagglutinin; ILK, integrin-linked kinase; KD, kinase deficient; LEF, lymphoid enhancer factor; PI-3, phosphatidylinositol 3; PKB, protein kinase B; TCF, T cell factor; WT, wild-type.
Received:
January 19 2001
Revision Requested:
April 30 2001
Accepted:
May 01 2001
Online ISSN: 1540-8140
Print ISSN: 0021-9525
© 2001 The Rockefeller University Press
2001
The Rockefeller University Press
J Cell Biol (2001) 153 (6): 1161–1174.
Article history
Received:
January 19 2001
Revision Requested:
April 30 2001
Accepted:
May 01 2001
Citation
Sujata Persad, Armelle A.Troussard, Timothy R. McPhee, David J. Mulholland, Shoukat Dedhar; Tumor Suppressor Pten Inhibits Nuclear Accumulation of β-Catenin and T Cell/Lymphoid Enhancer Factor 1–Mediated Transcriptional Activation. J Cell Biol 11 June 2001; 153 (6): 1161–1174. doi: https://doi.org/10.1083/jcb.153.6.1161
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionEmail alerts
Advertisement
Advertisement